This Day On The Street
Continue to site right-arrow
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

IntegraMed America's CEO Discusses Q3 2011 Results - Earnings Call Transcript

On the fertility center acquisition front, we’re maintain an active process of pursuing deals. We remain highly disciplined on valuation and return on investment criteria in these efforts to ensure new acquisitions deliver appropriate returns and present the right risk/reward profile. It’s difficult to predict when the next acquisition will occur but we remain confident that IntegraMed offers the best strategy for a standalone fertility center to gain the scale necessary to be competitive in today’s changing healthcare market.

We do believe the market is overdue for more consolidation. One example is Florida which is a very fragmented market where consolidation seems destined to take place given the challenges in obtaining organic growth and the high fixed costs of maintaining a fertility center. On a more general scale, markets across the US continue to be impacted for a third consecutive year by the overall softness in the economy, which we believe is causing physicians to rethink their operational strategies and goals. We have a variety of structures that can work including in-market mergers or outright acquisitions of mid-sized and large centers.

In summary, the fertility business is performing well despite the headwinds the fertility market continues to face. These challenges create opportunities for our firm and we will remain focused on operational performance and on expanding the business as prudent opportunities allow.

Moving to vein clinics, this segment delivered very strong top line performance, principally from the contribution of $3.7 million in incremental revenue from new clinics on top of stable mature clinic performance. Overall vein clinics posted record revenues each month of the quarter, underscoring the benefit of our new clinic expansion activity.

As for mature clinic revenue, the major issue there is that many of our clinics are at or near capacity both in terms of labor resources as well as physical capacity. To address these issues we’ve started to expand the footprint of certain of our clinics, adding additional personnel and implementing some operational changes that address treatment bottlenecks. As we gain experience from these changes we’ll be in a position to apply them to other facilities.

Read the rest of this transcript for free on seekingalpha.com

3 of 3

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
SYM TRADE IT LAST %CHG

Markets

DOW 17,698.18 -77.94 -0.44%
S&P 500 2,059.69 -8.20 -0.40%
NASDAQ 4,880.2280 -20.6570 -0.42%

Partners Compare Online Brokers

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs